We are live on ! Find out more
CRBP icon

Corbus Pharmaceuticals
CRBP

88 hedge funds and large institutions have $150M invested in Corbus Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

286% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 7

106% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 16

38% more capital invested

Capital invested by funds: $109M → $150M (+$41.1M)

28% more funds holding

Funds holding: 69 → 88 (+19)

0.27% more ownership

Funds ownership: 1.01% → 1.28% (+0.27%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

81% less call options, than puts

Call options by funds: $263K | Put options by funds: $1.4M

Holders
88
Holders Change
+19
Holders Change %
+27.54%
% of All Funds
2%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
27
Increased
33
Reduced
16
Closed
7
Calls
$263K
Puts
$1.4M
Net Calls
-$1.13M
Net Calls Change
-$339K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$9.63M
2
BlackRock
BlackRock
New York
+$7.11M
3
BBA
Baker Bros. Advisors
New York
+$4.71M
4
GPP
Great Point Partners
Connecticut
+$4.28M
5
Morgan Stanley
Morgan Stanley
New York
+$3.31M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.11M
2
PA
Perceptive Advisors
New York
-$1.53M
3
AA
ALPS Advisors
Colorado
-$354K
4
GCP
GSA Capital Partners
United Kingdom
-$245K
5
NFA
Nationwide Fund Advisors
Ohio
-$179K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
76
Ameritas Investment Partners
Nebraska
$28K – – –
Royal Bank of Canada
77
Royal Bank of Canada
Ontario, Canada
$13K -$23.1K -108 -64%
Macquarie Group
78
Macquarie Group
Australia
$9K +$8.56K +40 New
TRCT
79
Tower Research Capital (TRC)
New York
$8K -$7.06K -33 -46%
UBS Group
80
UBS Group
Switzerland
$7K -$16.1K -75 -69%
IWM
81
IHT Wealth Management
Illinois
$6K – – –
US Bancorp
82
US Bancorp
Minnesota
$6K – – –
TWA
83
TCI Wealth Advisors
Arizona
$4K – – –
AF
84
Advisornet Financial
Minnesota
$4K +$4.5K +21 New
TC
85
Trust Company
Kansas
$1K – – –
CA
86
Calton & Associates
Florida
$1K +$1.5K +7 New
MAM
87
Meeder Asset Management
Ohio
$1K +$1.5K +7 New
AA
88
ALPS Advisors
Colorado
– -$354K -1,649 Closed
NFA
89
Nationwide Fund Advisors
Ohio
– -$179K -834 Closed
HCM
90
Highbridge Capital Management
New York
– -$141K -659 Closed
PAG
91
Private Advisor Group
New Jersey
– -$97K -458 Closed
SPIA
92
Steward Partners Investment Advisory
New York
– -$2K -10 Closed
GT
93
Glenmede Trust
Pennsylvania
– -$1K -5 Closed
GI
94
Gradient Investments
Minnesota
– +$214 +1 New
1 2 3
4

CRBP Hedge Fund Activity: Q4 2017 in Review

88 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Corbus Pharmaceuticals (CRBP) for Q4 2017, worth a combined $150M — up 38% from $109M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CRBP positions and 7 closed out — a net gain of 20 holders — while 33 added to existing stakes and 16 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $9.63M. The largest seller was Millennium Management, cutting an estimated $2.11M.

  • 88 institutional investors held Corbus Pharmaceuticals (CRBP) as of Q4 2017, up from 69 in Q3 2017.
  • Funds reported $150M of Corbus Pharmaceuticals stock for Q4 2017, up 38% quarter-over-quarter.
  • 27 funds opened new Corbus Pharmaceuticals positions in Q4 2017 and 7 closed out, a net change of +20 holders.
  • The largest Corbus Pharmaceuticals buyer in Q4 2017 was Fidelity Investments, an estimated $9.63M added.
  • The largest Corbus Pharmaceuticals seller in Q4 2017 was Millennium Management, an estimated $2.11M sold.

Based on aggregated 13F filings for Q4 2017.